12 results about "Have Difficulty Swallowing" patented technology

The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation. The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-CL® tablet. Moreover, the extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration for patients who have difficulty swallowing tablets or capsules, e.g., paediatric patients or geriatrics.

A blonanserin oral soluble film composition, comprising an active drug, a film-forming material, and a plasticizer. The active drug is one or more of 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocyclooctapyridine as represented by formula I and a pharmaceutically acceptable salt, a hydrate, and a solvate thereof. The blonanserin oral soluble film composition has the advantages of thin thickness, good taste, stable properties, good dissolution rate, instant dissolution in the oral cavity without drinking water, particular suitability for patients suffering from dysphagia, no gravel feeling after dissolution in the oral cavity, and fast oral absorption rate. The composition also has a uniform appearance, good flexibility, a simple process, no sedimentation in the process of film liquid preparation, content uniformity meeting the requirements, a high drug loading capacity, and good marketing prospects.

The invention relates to the technical field of medicines, in particular to ibuprofen water-free swallowing granules and a preparation method thereof. The ibuprofen water-free swallowing particles are composed of medicine carrying particles and taste modifying particles. The medicine-carrying particles comprise the following components in percentage by weight: 50.0 to 95.0 percent of ibuprofen, 0 to 20.0 percent of disintegrating agent, 0.5 to 25.0 percent of adhesive and 0 to 50.0 percent of filling agent. The invention further discloses a preparation method of the medicine-carrying particles. The mass ratio of the ibuprofen to the disintegrating agent to the adhesive is (80-90): (0-10): (5-20). And the adhesive is selected from a low-melting-point adhesive. The medicine-carrying particles are granulated by a hot-melting granulator and then mixed with the taste-modifying particles. The ibuprofen water-free swallowing granules prepared by the invention are convenient to carry, can be rapidly disintegrated in the oral cavity and rapidly release medicines, enter gastrointestinal tracts along with swallowing actions to be absorbed, do not need to be swallowed by water, and are good in medication compliance and particularly suitable for patients with swallowing difficulty to take.

Disclosed is a method for treating dysphagia comprising: fitting a patient afflicted with dysphagia with a TRP oral retainer-based device having an arch for limiting movement of the patient's tongue, the device to be worn by the patient at night starting at about bedtime and during sleep, preferably for at least 8 hours; providing instructions to the patient to wear the device nightly for a period of time from about 2 to about 18 months (the wearing period) as indicated; monitoring the patient's tongue pressure at one or more time points during the wearing period, wherein an increase in tongue strength, as measured for example by tongue pressure (TP) compared to baseline or compared to a prior monitoring time point during the wearing period, indicates that the patient receives a benefit from wearing the device. An increase in tongue strength has been shown to correlate closely with reducing oropharyngeal dysphagia and its attendant symptoms and pathologies.

The present invention relates to a stable and palatable formulation containing a high content of meglustat, which can be used in particular by children or persons with dysphagia. This highly concentrated formulation contains at least 150 mg / mL of megranurite, and as excipients sodium benzoate, tartaric acid, a sweetener, and optionally an acidic flavoring. This formulation can advantageously be administered with a therapeutic bienzyme activator to alleviate the intestinal side effects of Magrude.

Provided are an oral dissolving film composition of rivaroxaban, a method for preparing same, and use thereof. The oral dissolving film composition comprises one or more of rivaroxaban and a pharmaceutically acceptable salt, hydrate, and solvate thereof as an active ingredient, and a film-forming material. Also, the present invention features a simple process, no sedimentation during the preparation of film solutions, qualified content uniformity, high drug loading capacity, and improved patient compliance, and is particularly suitable for patients with dysphagia.

This invention provides an orally soluble film composition for rivaroxaban, its preparation method, and its applications. The rivaroxaban orally soluble film composition comprises an active pharmaceutical ingredient and a film-forming material; the active pharmaceutical ingredient is one or more of the following: 5-chloro-nitro-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholino)phenyl]-1,3-azolidin-5-yl}methyl)-2-thiophene-carboxamide, a pharmaceutically acceptable salt, hydrate, and solvate thereof, as shown in Formula I. The rivaroxaban orally soluble film composition provided by this invention has the advantages of good taste, stable properties, high dissolution, and immediate dissolution in the oral cavity without the need for drinking water, without a gritty feeling after dissolution in the oral cavity, and rapid oral absorption. Furthermore, the process of this invention is simple, no sedimentation occurs during the preparation of the film solution, the content uniformity meets requirements, the drug loading is high, and clinical patient compliance is improved, making it particularly suitable for patients with swallowing difficulties, and it has good market prospects.

This invention provides a cariprazine orally disintegrating film composition, its preparation method, and its application. The orally disintegrating film composition comprises an active ingredient, a film-forming material, and a plasticizer, wherein the active ingredient is selected from one or more mixtures of cariprazine, pharmaceutically acceptable salts of cariprazine, and their inclusion compounds. The orally disintegrating film composition of this invention has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without water, and rapid oral absorption. It also features a simple process, high drug loading capacity, and good drug content uniformity. The orally disintegrating film composition of this invention helps improve medication compliance, medication retention, and vomiting in patients with schizophrenia, and is particularly suitable for patients with swallowing difficulties, showing promising market prospects.

The present invention discloses novel innovative compositions containing concentrated mucus extracted from okra, as well as methods of making these compositions. At least a portion of the composition may be used in a ready to drink (RTD) beverage or as a powder, and may be used to treat an individual with dysphagia. One example method includes at least one step selected from the group consisting of: precooking fresh or frozen whole okra pods; cutting the okra into slices; immersing the okra slices in water; separating an okra mucus concentrate from the okra tablets by filtration; adding an excipient material; the mixture containing the okra mucus concentrated solution is homogenized; subjecting the mixture to heat treatment or sterilization; and adjusting the okra mucus concentration in the heat-treated or sterilized mixture to achieve a relaxation time at 20 DEG C of at least 10 milliseconds, preferably 50 milliseconds to 400 milliseconds and most preferably 100 milliseconds to 200 milliseconds.

Clofazimine (CFZ) is an important component of a full oral pharmaceutical regimen recommended by the World Health Organization (WHO) for the treatment of multidrug resistant tuberculosis (MDR-TB). However, the lack of the divisible oral dosage form has limited the use of the medicament in pediatric populations that may require reduced doses to reduce the likelihood of adverse drug events. Pediatric friendly CFZ mini-tablets prepared from micronized powder via direct compression at relatively high drug loading provide suitable dosage forms for 6-month-old children as well as patients with whole capsules or difficult tablet swallowing.

The invention discloses a sevelamer carbonate dry suspension and a preparation method thereof.The sevelamer carbonate dry suspension is prepared from, by mass, 94.81%-95.07% of a sevelamer carbonate raw material, 0.11%-1.30% of a suspending aid and other auxiliary materials, and the suspending aid is selected from one or more of sodium carboxymethyl cellulose, a microcrystalline cellulose-sodium carboxymethyl cellulose compound, xanthan gum and hydroxypropyl methylcellulose. Compared with the prior art, the sevelamer carbonate dry suspension has the advantages that the sevelamer carbonate raw material in the sevelamer carbonate dry suspension is high in proportion, and the suspending aid in the sevelamer carbonate dry suspension is low in proportion, so that grit feeling caused by oral administration of the suspension is effectively reduced, the stability and taste of the suspension are improved, the deposition speed of the medicine suspension is reduced, and a patient can uniformly take in the medicine when taking the sevelamer carbonate dry suspension; the method is particularly important for patients suffering from dysphagia or oral sensitivity.

The application provides a cariprazine orally dissolving film composition, a preparation method and application thereof. The orally dissolving film composition comprises an active ingredient, a film forming material and a plasticizer, wherein the active ingredient is selected from a mixture of one or more of cariprazine, a pharmaceutically acceptable salt of cariprazine and an inclusion compound thereof. The orally dissolving film composition has the advantages of thin thickness, good taste, stable property, instant dissolving in the oral cavity without drinking water, fast oral absorption speed, simple process, high drug loading, good drug content uniformity, and the like. The orally dissolving film composition helps to improve the poor compliance, hiding and spitting of patients with schizophrenia, and is particularly suitable for patients with difficulty in swallowing, and has a good market prospect.